(Q58828834)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

title

Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Guy Toner

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Ganessan Kichenadasse

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

author name string

I N Olver

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

P Grimison

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

M R Stockler

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

V Gebski

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

R Harrup

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

C Underhill

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

N Singhal

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

I D Davis

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A Boland

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

A McDonald

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

D Thomson

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

Australian and New Zealand Urogenital and Prostate Cancer Trials Group

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

publication date

30 December 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

Supportive Care in Cancer

21 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

page(s)

1561-1568

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00520-012-1696-0

21 February 2020

exact match

0 references

cites work

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Palonosetron plus dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy for germ cell cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Understanding the concept of chemotherapy-related nausea: the patient experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Prevention of chemotherapy-induced nausea and vomiting: focus on fosaprepitant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00520-012-1696-0

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23274926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cispla

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23274926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/23274926

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00520-012-1696-0

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23274926%20AND%20SRC:MED&resulttype=core&format=json

21 February 2020

1 reference